Protara Therapeutics
TARA
33 hedge funds and large institutions have $16M invested in Protara Therapeutics in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 5 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5.05% less ownership
Funds ownership: 57.74% → 52.69% (-5.1%)
6% less funds holding
Funds holding: 35 → 33 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
52% less capital invested
Capital invested by funds: $33.2M → $16M (-$17.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$60.7K |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$53.6K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$37.1K |
| 4 |
VF
Virtu Financial
New York
|
+$36.9K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$781K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$599K |
| 3 |
PA
Perceptive Advisors
New York
|
-$342K |
| 4 |
DAM
DLD Asset Management
New York
|
-$264K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$141K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $5K | +$6.61K | +1,807 | New |
|
27
UBS Group
Zurich,
Switzerland
| $4K | +$2.55K | +697 | +121% |
|
|
O
28
OrbiMed
New York
| $2.43K | – | – | – |
|
29
Federated Hermes
Pittsburgh,
Pennsylvania
| $1K | -$168 | -46 | -11% |
|
30
Wells Fargo
San Francisco,
California
| $1K | +$22 | +6 | +1% |
|
31
JP Morgan Chase
New York
| $1K | +$1.29K | +352 | New |
|
|
APA
32
American Portfolios Advisors
Holbrook,
New York
| $293 | – | – | – |
|
|
33
Goldman Sachs
New York
| – | -$781K | -152,847 | Closed |
|
|
TI
34
Trexquant Investment
Stamford,
Connecticut
| – | -$83K | -16,313 | Closed |
|
|
PCM
35
Prelude Capital Management
New York
| – | -$66K | -12,872 | Closed |
|
36
Barclays
London,
United Kingdom
| – | -$13K | -2,510 | Closed |
|
37
Bank of America
Charlotte,
North Carolina
| – | -$3K | -745 | Closed |
|
38
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$168 | -46 | -32% |
|
TARA Hedge Fund Activity: Q2 2022 in Review
33 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q2 2022, worth a combined $16M — down 52% from $33.2M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TARA and 3 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $60.7K. The largest seller was Goldman Sachs, exiting entirely with an estimated $781K sold.
- 33 institutional investors held Protara Therapeutics (TARA) as of Q2 2022, down from 35 in Q1 2022.
- Funds reported $16M of Protara Therapeutics stock for Q2 2022, down 52% quarter-over-quarter.
- 3 funds opened new Protara Therapeutics positions in Q2 2022 and 5 closed out, a net change of -2 holders.
- The largest Protara Therapeutics buyer in Q2 2022 was Renaissance Technologies, an estimated $60.7K added.
- The largest Protara Therapeutics seller in Q2 2022 was Goldman Sachs, an estimated $781K sold.
Based on aggregated 13F filings for Q2 2022.